186 related articles for article (PubMed ID: 37347751)
1. An oncogenic CTNNB1 mutation is predictive of post-operative recurrence-free survival in an EGFR-mutant lung adenocarcinoma.
Kim Y; Ahn B; Yoon S; Lee G; Kim D; Chun SM; Kim HR; Jang SJ; Hwang HS
PLoS One; 2023; 18(6):e0287256. PubMed ID: 37347751
[TBL] [Abstract][Full Text] [Related]
2. Non-small cell lung carcinomas with CTNNB1 (beta-catenin) mutations: A clinicopathological study of 26 cases.
Thomas de Montpréville V; Lacroix L; Rouleau E; Mamodaly M; Leclerc J; Tutuianu L; Planchard D; Boulate D; Mercier O; Besse B; Fadel É; Ghigna MR
Ann Diagn Pathol; 2020 Jun; 46():151522. PubMed ID: 32442860
[TBL] [Abstract][Full Text] [Related]
3. Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma.
Lee JS; Kim EK; Kim KA; Shim HS
Cancer Res Treat; 2024 Jan; 56(1):104-114. PubMed ID: 37499696
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic characteristics of FBXW7-mutated colorectal adenocarcinoma and association with aberrant beta-catenin localization.
Escobar D; Bushara O; Sun L; Liao J; Yang GY
Hum Pathol; 2022 Jan; 119():51-58. PubMed ID: 34717891
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
[TBL] [Abstract][Full Text] [Related]
6. β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation.
Geyer FC; Lacroix-Triki M; Savage K; Arnedos M; Lambros MB; MacKay A; Natrajan R; Reis-Filho JS
Mod Pathol; 2011 Feb; 24(2):209-31. PubMed ID: 21076461
[TBL] [Abstract][Full Text] [Related]
7. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
Kadara H; Choi M; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Yoo Y; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Wistuba II; Herbst RS
Ann Oncol; 2017 Jan; 28(1):75-82. PubMed ID: 27687306
[TBL] [Abstract][Full Text] [Related]
8. GNAS mutation as an alternative mechanism of activation of the Wnt/β-catenin signaling pathway in gastric adenocarcinoma of the fundic gland type.
Nomura R; Saito T; Mitomi H; Hidaka Y; Lee SY; Watanabe S; Yao T
Hum Pathol; 2014 Dec; 45(12):2488-96. PubMed ID: 25288233
[TBL] [Abstract][Full Text] [Related]
9. Recurrent Mutations in APC and CTNNB1 and Activated Wnt/β-catenin Signaling in Intraductal Papillary Neoplasms of the Bile Duct: A Whole Exome Sequencing Study.
Fujikura K; Akita M; Ajiki T; Fukumoto T; Itoh T; Zen Y
Am J Surg Pathol; 2018 Dec; 42(12):1674-1685. PubMed ID: 30212390
[TBL] [Abstract][Full Text] [Related]
10. Alteration in the Wnt/β-catenin signaling pathway in gastric neoplasias of fundic gland (chief cell predominant) type.
Hidaka Y; Mitomi H; Saito T; Takahashi M; Lee SY; Matsumoto K; Yao T; Watanabe S
Hum Pathol; 2013 Nov; 44(11):2438-48. PubMed ID: 24011952
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological analysis of β-catenin and Axin-1 in solid pseudopapillary neoplasms of the pancreas.
Huang SC; Ng KF; Yeh TS; Chang HC; Su CY; Chen TC
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S438-46. PubMed ID: 21769465
[TBL] [Abstract][Full Text] [Related]
12. The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma.
Zhou W; Liu Z; Wang Y; Zhang Y; Qian F; Lu J; Wang H; Gu P; Hu M; Chen Y; Yang Z; Zhao R; Lou Y; Han B; Zhang W
Cancer Med; 2022 Mar; 11(5):1299-1309. PubMed ID: 35023616
[TBL] [Abstract][Full Text] [Related]
13. Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors.
Bonnet S; Gaujoux S; Launay P; Baudry C; Chokri I; Ragazzon B; Libé R; René-Corail F; Audebourg A; Vacher-Lavenu MC; Groussin L; Bertagna X; Dousset B; Bertherat J; Tissier F
J Clin Endocrinol Metab; 2011 Feb; 96(2):E419-26. PubMed ID: 21084400
[TBL] [Abstract][Full Text] [Related]
14. Aberrant nuclear localization and gene mutation of beta-catenin in low-grade adenocarcinoma of fetal lung type: up-regulation of the Wnt signaling pathway may be a common denominator for the development of tumors that form morules.
Nakatani Y; Masudo K; Miyagi Y; Inayama Y; Kawano N; Tanaka Y; Kato K; Ito T; Kitamura H; Nagashima Y; Yamanaka S; Nakamura N; Sano J; Ogawa N; Ishiwa N; Notohara K; Resl M; Mark EJ
Mod Pathol; 2002 Jun; 15(6):617-24. PubMed ID: 12065775
[TBL] [Abstract][Full Text] [Related]
15. Novel gene mutations in well-differentiated fetal adenocarcinoma of the lung in the next generation sequencing era.
Fu Y; Wu Q; Su F; Tang Y; Lin Y; Wang W; Jiang L
Lung Cancer; 2018 Oct; 124():1-5. PubMed ID: 30268445
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer.
Moroney MR; Woodruff E; Qamar L; Bradford AP; Wolsky R; Bitler BG; Corr BR
Mol Carcinog; 2021 Aug; 60(8):511-523. PubMed ID: 34038589
[TBL] [Abstract][Full Text] [Related]
17. Nuclear β-catenin localization and mutation of the CTNNB1 gene: a context-dependent association.
Kim G; Kurnit KC; Djordjevic B; Singh C; Munsell MF; Wang WL; Lazar AJ; Zhang W; Broaddus R
Mod Pathol; 2018 Oct; 31(10):1553-1559. PubMed ID: 29795437
[TBL] [Abstract][Full Text] [Related]
18. EGFR mutation is not a prognostic factor for CNS metastasis in curatively resected lung adenocarcinoma patients.
Liu X; Li X; Zhang C; Jin J; Wang Z; Xiao R; Sun K; Wang J; Zhong W; Yang F
Lung Cancer; 2022 May; 167():78-86. PubMed ID: 35427848
[TBL] [Abstract][Full Text] [Related]
19. CTNNB1 Mutations and Aberrant β-Catenin Expression in Ovarian Endometrioid Carcinoma: Correlation With Patient Outcome.
Zyla RE; Olkhov-Mitsel E; Amemiya Y; Bassiouny D; Seth A; Djordjevic B; Nofech-Mozes S; Parra-Herran C
Am J Surg Pathol; 2021 Jan; 45(1):68-76. PubMed ID: 32769429
[TBL] [Abstract][Full Text] [Related]
20. An immunohistochemical approach to detect oncogenic CTNNB1 mutations in primary neoplastic tissues.
Akyol A; Güner G; Özşeker HS; Işık A; Atcı Ö; Uzun S; Atayar E; Ozaltin F; Gedikoğlu G; Sökmensüer C; Fearon ER
Lab Invest; 2019 Jan; 99(1):128-137. PubMed ID: 30177831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
